TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06340737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22CART Infusion
Description: Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22CART Infusion
Description: Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22CART Infusion
Description: Dosing and Administration Participants will be hospitalized to receive treatment with CD22CART, if not previously hospitalized, and will remain hospitalized for approximately 5 to 7 (±2) days. Patients may be discharged once all AEs have resolved to Grade 1 or better, or at the discretion of the treating physician. Participants may be discharged with non critical and clinically stable or slowly improving toxicities (e.g., renal insufficiency, cytopenias) even if \> Grade 1, if deemed appropriate by the investigator.
Study: NCT05610891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 131
Description: CLR 131 will be administered IV (intravenously) at a dose based on patients' BSA
Study: NCT05941182

Intervention type: OTHER
Intervention: online questionnaires
Description: Before and after online questionnaires

Intervention type: OTHER
Intervention: online questionnaires
Description: Before and after online questionnaires
Study: NCT05212116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 is presented as low dose, and high dose capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 is presented as low dose, and high dose capsules.
Study: NCT06289621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: False Safety Behavioral Elimination Treatment (FSET)
Description: 5-session transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Standard Care
Description: Participants in the enhanced standard care control group will receive treatment as usual and a list referrals.
Study: NCT05338398

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bocaliner
Description: Bocaliner is a soft, orally inserted device that has been demonstrated to increase the oral retention of oral, topical therapies such as mouthwashes and gels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzydamine
Description: Benzydamine is an anti-inflammatory and antibiotic mouthwash that has shown promise for the treatment of radiation-induced oral mucositis.
Study: NCT04676555

Intervention type: DRUG
Intervention: Ocrelizumab
Description: There is no treatment allocation. Patients administered Ocrelizumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: DRUG
Intervention: Ofatumumab
Description: There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05606653

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of critical airway closing pressure
Description: Measurement of critical airway closing pressure

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of critical airway closing pressure
Description: Measurement of critical airway closing pressure

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of critical airway closing pressure
Description: Measurement of critical airway closing pressure

Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory function tests
Description: CO2 response test

Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory function tests
Description: CO2 response test

Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory function tests
Description: CO2 response test

Intervention type: OTHER
Group type: OTHER
Intervention: pharyngometry
Description: measure of the pharyngometry

Intervention type: OTHER
Group type: OTHER
Intervention: pharyngometry
Description: measure of the pharyngometry

Intervention type: OTHER
Group type: OTHER
Intervention: pharyngometry
Description: measure of the pharyngometry
Study: NCT05993975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain 0.5%
Description: Bupivacaine hydrochloride was given without any adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain 0.5%
Description: Bupivacaine hydrochloride was given without any adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Use of Dexmedetomidine Hydrochloride 5 micrograms (1 mL) as an adjuvant with bupivacaine hydrochloride
Study: NCT05212116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Matching Placebo for SDI-118 is mannitol in capsules.
Study: NCT05623592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 17,5/15/10 mg Methotrexate subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride subcutaneously
Study: NCT04876716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azole
Description: Dosing according to the SPC
Study: NCT06325475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: labor with neuraxial labor analgesia
Description: Pregnant women in Group A will receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group A will receive 0.0625% bupivacaine via epidural route.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: labour without noroaxial labor analgesia
Description: Pregnant women in Group B will not receive neuraxial labor analgesia (dural puncture epidural or combined spino epidural analgesia).~If postpartum analgesic needs arise, patients in Group B will receive iboprufen and acetaminophen.
Study: NCT05802849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.
Study: NCT05543382

Intervention type: DEVICE
Intervention: Axonics System
Description: The Axonics System will be implanted as standard care

Intervention type: DEVICE
Intervention: Axonics System
Description: The Axonics System will be implanted as standard care
Study: NCT05156814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston® 1, Femoston® 2
Description: Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duphaston
Description: Duphaston®, 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klimadynon
Description: Cimicifuga racemosa rhizomatum extract

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divigel
Description: Divigel, 0.1%
Study: NCT05389371

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alberta Healthy Living Program
Description: Weight management services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alberta Obesity Centre Program
Description: Multi-disciplinary obesity management
Study: NCT06458660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPP+: Mindfulness Meditation Delivered
Description: During the 6-week intervention period, participants will receive reminder SMS text messages at a time selected by the participant at 48 and 24-hrs before each scheduled study visit. Within 24 hours after every session, participants will receive an SMS text reminder to complete a session satisfaction survey. If the satisfaction surveys are not completed within 48 hours after each session, participants will receive an additional SMS text message once per day for three consecutive days after each planned study visit. Twenty-four hours before each scheduled study visit after study visit number 1, participants will an SMS text requiring a one-character response (1= yes, 2=no), asking if participants practiced any mindfulness meditation techniques since the last session. Participants who have not interacted with the app during the previous week will receive an accountability call to assess barriers to participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LP
Description: LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
Study: NCT05389371

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Osteoarthritis advice
Description: Living Your Best Life with Osteoarthritis Handbook

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoarthritis advice
Description: Living Your Best Life with Osteoarthritis Handbook

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: GLA:D physiotherapy programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: GLA:D physiotherapy programs.
Study: NCT06269549

Intervention type: OTHER
Group type: OTHER
Intervention: Non-training Real Dietary Supplement (G1)
Description: One Active Joint capsule thrice daily, and one sachet (10g) Collagen Powder Blend once daily

Intervention type: OTHER
Group type: OTHER
Intervention: Training Placebo Dietary Supplement (G2)
Description: One Active Joint placebo capsule thrice daily, and one sachet (10g) Collagen Powder Blend placebo once daily + physical exercise (60 minutes per session twice a week)

Intervention type: OTHER
Group type: OTHER
Intervention: Training Real Dietary Supplement (G3)
Description: One Active Joint capsule thrice daily, and one sachet (10g) Collagen Powder Blend once daily + physical exercise (60 minutes per session twice a week)

Intervention type: OTHER
Group type: OTHER
Intervention: Training Real Dietary Supplement (G3)
Description: One Active Joint capsule thrice daily, and one sachet (10g) Collagen Powder Blend once daily + physical exercise (60 minutes per session twice a week)
Study: NCT06111573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Study group using Vitamin D for myofascial pain treatment. Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Study group usind Vitamin D for myofascial pain treatment. Medical treatment with Vitamin D (10,000 IU/day) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Control group using Diclofenac Sodium for myofascial pain treatment. Medical treatment with Diclofenac Sodium (Voltaren 75 mg, 2x1 ) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers.
Study: NCT05640232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDE100 association
Description: Experimental drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buscopan® Composto association
Description: Active comparator.
Study: NCT04988516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. The research nurse will be able to complete any information should they find it incomplete or substandard.
Study: NCT05061888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smart Intervention for Food Waste Management and Replacing current diet with Fruits and Vegetables
Description: Will receive a Smart Intervention on Food Waste Management and replacing less healthy foods with fruits and vegetables.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smart Intervention for Stress Managment
Description: Will receive a Smart Intervention on stress management practices and strategies.
Study: NCT06637917

Intervention type: DEVICE
Intervention: OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System
Description: The Nellcor™ N-600x Pulse Oximetry System with N-600X Pulse Oximeter and Nellcor™ Sensors and Cables with OxiMax technology is indicated for prescription use only for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin and PR. The N-600x Pulse Oximeter is intended for use with neonatal, pediatric, and adult patients during both no motion and motion conditions and for patients who are either well or poorly perfused, in hospitals, hospital-type facilities, intra-hospital transport, and home environments.

Intervention type: DEVICE
Intervention: LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter
Description: The Masimo Rad-97™ and accessories are indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin, PR, carboxyhemoglobin saturation (SpCO), methemoglobin saturation (SpMet), total hemoglobin concentration (SpHb), and/or acoustic respiratory rate (RRa). The Masimo Rad-97™ and accessories are indicated for use with adult, pediatric, and neonatal patients during both no motion and motion conditions, and for patients who are well or poorly perfused. In addition, the Masimo Rad-97™ and accessories are indicated to provide the continuous non-invasive monitoring data obtained from the Masimo Rad-97™ and accessories for functional oxygen saturation of arterial hemoglobin and PR to multi-parameter devices for the display on those devices.

Intervention type: DEVICE
Intervention: 1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor
Description: Market-released ECG monitoring system
Study: NCT05435248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10375
Description: HS-10375 will be administered orally once daily in a continuous regimen
Study: NCT05344092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VetEd Mobile Application
Description: Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
Study: NCT04364672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-labeled DPA-714 PET scan
Description: One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
Study: NCT05331664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Standard of care surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Standard of care surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Sub-tenon injection of triamcinolone acetonide (40mg/mL) at the time of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin
Description: Antibiotic eye drop 4 times per day for 1 week after surgery
Study: NCT06002022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBECCA system (smartwatch + mobile app use)
Description: Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment
Study: NCT06781632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)
Study: NCT05109234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Film-coated tablet
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam oral solution
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
Study: NCT06242080

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness meditation has been described as a behavioral technique involving the intentional self-regulation of attention to present-moment experience, combined with release of cognitive fixation on thoughts (whether simple images or complex story lines) regarding the past or future. Through training in mindfulness, individuals learn to evoke and sustain a non-judgmental state of present-moment awareness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness meditation has been described as a behavioral technique involving the intentional self-regulation of attention to present-moment experience, combined with release of cognitive fixation on thoughts (whether simple images or complex story lines) regarding the past or future. Through training in mindfulness, individuals learn to evoke and sustain a non-judgmental state of present-moment awareness.
Study: NCT04941274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: An initial dose of 200 mg twice daily and at an MTD dose will be administered orally every day of each 28-day cycle.
Study: NCT06414317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment of Distress
Description: Undergo psychological distress screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation Visit
Description: Attend consultations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Undergo malnutrition screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive access to bladder cancer ENST

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Attend virtual support group meetings
Study: NCT04701437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentor
Description: Peer mentors will contact participants within 72 hours of enrollment to discuss the early release period, gauge their readiness for HCV treatment, and identify ancillary needs. They will also accompany the participant to their first medical appointment with an HCV provider and any future appointments if requested by the participant. Peer mentors will offer participants social support throughout the 6 months they are enrolled in the study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Passive referral to a HCV provider
Study: NCT06469073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block or Erector spinal plane block
Description: Transversus thoracic muscle plane block or Erector spinal plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus thoracic muscle plane block or Erector spinal plane block
Description: Transversus thoracic muscle plane block or Erector spinal plane block
Study: NCT04876716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azole
Description: Dosing according to the SPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: 200mg loading dose on day 1 and 100mg QD thereafter